NDAC meeting
This article was originally published in The Tan Sheet
Executive Summary
FDA's Pulmonary & Allergy, Dermatologic & Ophthalmologic Drugs Advisory Committees will join NDAC in deliberations on OTC switch of Schering-Plough's Claritin (loratadine). April 22 public meeting will focus on chronic idiopathic urticaria as an OTC indication (1"The Tan Sheet" March 18, 2002, In Brief). Committees also will meet in closed-door session April 23. Individuals wishing to speak at April 22 meeting must file written submissions by April 12...